Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation

Blood

Volumn 107, Issue 7, 2006, Pages 3002-3008

  Einsele, Hermann ^a   Reusser, Pierre ^b   Bornhäuser, Martin ^b   Kalhs, Peter ^b   Ehninger, Gerhard ^b   Hebart, Holger ^b   Chalandon, Yves ^b   Kröger, Nicolaus ^b   Hertenstein, Bernd ^b   Rohde, Frank ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HUMAN; INTERSTITIAL PNEUMONIA; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; PANCYTOPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPERINFECTION; THROMBOCYTOPENIC PURPURA;

EID: 33645521564     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3786     Document Type: Article

References (26)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478-488.
2. Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation: risk factors and response to therapy. Transplantation. 1993;55:1339-1346.
3. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173-178.
4. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179-184.
5. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005-1011.
6. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601-1607.
7. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815-2820.
8. Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation. 1998;66:1330-1334.
9. Reusser P, Einsele H, Lee J, et al. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation: randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99:1159-1164.
10. Boeckh M, Huang M, Ferrenberg J, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol. 2004;42:1142-1148.
11. Pellegrin I, Garrigue I, Binquet C, et al. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J Clin Microbiol. 1999;37:3124-3132.
12. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol. 1999;39:800-804.
13. Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV-and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37:167-176.
14. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44:2811-2815.
15. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-620.
16. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis [erratum appears in N Engl J Med. 2002;347:862]. N Engl J Med. 2002;346:1119-1126.
17. Antin JH. Clinical practice: long-term care after hematopoietic-cell transplantation in adults. N Engl J Med. 2002;347:36-42.
18. Atkinson K, Biggs JC, Britton K, et al. Oral administration of cyclosporin A for recipients of allogeneic marrow transplants: implications of clinical gut dysfunction. Br J Haematol. 1984;56:223-231.
19. Boeckh M, Nichols WG, Marr KA. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med. 2002;347:1625-1626.
20. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097.
21. Signorini DF, Leung O, Simes RJ, Beller E, Gebski VJ, Callaghan T. Dynamic balanced randomization for clinical trials. Stat Med. 1993;12:2343-2350.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90:2502-2508.
24. Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25:757-763.
25. Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev. 2003;16:647-657.
26. Solano C, Munoz I, Gutierrez A, et al. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol. 2001;39:3938-3941.